Elia Seguí Highlights ATRACTIB Phase II Results in PDL1– mTNBC
Elia Seguí, Breast Cancer Medical Oncologist and Translational Researcher at Dana-Farber Cancer Institute, shared a post on LinkedIn:
“PDL1– mTNBC remains a major clinical challenge.
The ATRACTIB phase II trial explores a novel combination—chemotherapy (paclitaxel) + anti-VEGF (bevacizumab) + ICI (atezolimumab)—with encouraging results just published in Nature Medicine (Nature Portfolio).
What we already knew: In the 1L mTNBC setting, ICIs are not currently recommended for patients with PDL1– or low-expressing tumors (CPS <10), based on KEYNOTE-355. Antiangiogenic therapy has been proposed to enhance immune response by modifying the tumor microenvironment.
What’s new: This single-arm trial evaluated atezolizumab + bevacizumab + paclitaxel in 100 patients with advanced TNBC, regardless of PD-L1 status (most evaluable tumors were PD-L1– [97.6%]).
Median PFS: 11.0 months
ORR: 63% (14% CR)
Median OS: 27.4 months.
No new safety signals observed
These outcomes compare favorably with results from phase III trials in this setting (e.g. KEYNOTE-355 ITT population) and suggest this combination may help address the unmet need in PD-L1– mTNBC.
Why it matters: The study supports a potential role for ICI beyond PD-L1+ tumors, particularly when combined with antiangiogenic agents. This is especially timely as bispecific drugs targeting VEGF and PD-(L)1 are under clinical development.
Notably, at ASCO2025, the ABC study also showed a 77% intracranial response rate in patients with mTNBC and brain metastases treated with platinum + bevacizumab + anti–PD1, reinforcing the relevance of this combination strategy.
However, the single-arm design prevents assessment of each component’s contribution, and the lack of correlative analyses limits understanding of the mechanisms behind the observed clinical benefit.
Congrats to the authors!
Maria Gion et al. Atezolizumab plus paclitaxel and bevacizumab as first-line treatment of advanced triple-negative breast cancer: the ATRACTIB phase 2 trial.”
Title: Atezolizumab plus paclitaxel and bevacizumab as first-line treatment of advanced triple-negative breast cancer: the ATRACTIB phase 2 trial
Authors: María Gion, Isabel Blancas, Patricia Cortez-Castedo, Alfonso Cortés-Salgado, Frederik Marmé, Salvador Blanch, Serafín Morales, Nieves Díaz, Isabel Calvo-Plaza, Sabela Recalde, Alejandro Martínez-Bueno, Manuel Ruiz-Borrego, Elisenda Llabrés, María Teresa Taberner, Michelino de Laurentiis, Silvia García-Vicente, José Antonio Guerrero, Olga Boix, Jose Rodríguez-Morató, Miguel Sampayo-Cordero, Gabriele Antonarelli, José Manuel Pérez-García, Javier Cortés, Antonio Llombart-Cussac
You can read the Full Article on Nature Medicine
More posts featuring Elia Seguí.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023